AIM: To investigate whether nuclear and cytoplasmic Maspin expression is associated with distinct clinicopathological parameters and TP53 expression in a representative series of primary non-small cell lung cancer (NSCLC). METHODS: Tissue microarrays (n=487) were used to immunohistochemically analyse expression of Maspin and TP53. Cytoplasmic and nuclear expression of Maspin was scored on the basis of the percentage of positive tumour cells. Univariate analysis of clinicopathological variables potentially affecting tumour-specific survival was performed. RESULTS: Immunohistochemical Maspin expression (nuclear and cytoplasmic) was informative in 72.3% (352/487) of cases. Cytoplasmic and nuclear Maspin immunoreactivity in >or=10% of tumour cells was detected in 37.8% (133/352) and 65.3% (230/352) of informative cases, respectively. Nuclear and cytoplasmic Maspin staining was observed more frequently in primary squamous cell carcinomas than in other lung cancer types. Only nuclear Maspin immunoreactivity was significantly associated with positive TP53 staining. Cytoplasmic or nuclear Maspin expression was not associated with tumour-specific survival. CONCLUSION: Maspin expression was found both in the nucleus and the cytoplasm of NSCLC, more frequently in squamous cell carcinomas. However, no association with tumour-specific survival could be demonstrated.
AIM: To investigate whether nuclear and cytoplasmic Maspin expression is associated with distinct clinicopathological parameters and TP53 expression in a representative series of primary non-small cell lung cancer (NSCLC). METHODS: Tissue microarrays (n=487) were used to immunohistochemically analyse expression of Maspin and TP53. Cytoplasmic and nuclear expression of Maspin was scored on the basis of the percentage of positive tumour cells. Univariate analysis of clinicopathological variables potentially affecting tumour-specific survival was performed. RESULTS: Immunohistochemical Maspin expression (nuclear and cytoplasmic) was informative in 72.3% (352/487) of cases. Cytoplasmic and nuclear Maspin immunoreactivity in >or=10% of tumour cells was detected in 37.8% (133/352) and 65.3% (230/352) of informative cases, respectively. Nuclear and cytoplasmic Maspin staining was observed more frequently in primary squamous cell carcinomas than in other lung cancer types. Only nuclear Maspin immunoreactivity was significantly associated with positive TP53 staining. Cytoplasmic or nuclear Maspin expression was not associated with tumour-specific survival. CONCLUSION:Maspin expression was found both in the nucleus and the cytoplasm of NSCLC, more frequently in squamous cell carcinomas. However, no association with tumour-specific survival could be demonstrated.
Authors: Jim Heighway; Teresa Knapp; Lenetta Boyce; Shelley Brennand; John K Field; Daniel C Betticher; Daniel Ratschiller; Mathias Gugger; Michael Donovan; Amy Lasek; Paula Rickert Journal: Oncogene Date: 2002-10-31 Impact factor: 9.867
Authors: Nicolai Maass; Koichi Nagasaki; Martin Ziebart; Christoph Mundhenke; Walter Jonat Journal: Clin Breast Cancer Date: 2002-10 Impact factor: 3.225
Authors: T Hojo; Y Akiyama; K Nagasaki; K Maruyama; K Kikuchi; T Ikeda; M Kitajima; K Yamaguchi Journal: Cancer Lett Date: 2001-09-28 Impact factor: 8.679
Authors: Z Zou; C Gao; A K Nagaich; T Connell; S Saito; J W Moul; P Seth; E Appella; S Srivastava Journal: J Biol Chem Date: 2000-03-03 Impact factor: 5.157
Authors: Anil K Sood; Mavis S Fletcher; Lynn M Gruman; Jeremy E Coffin; Sarvenaz Jabbari; Zhila Khalkhali-Ellis; Nancy Arbour; Elisabeth A Seftor; Mary J C Hendrix Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: N Snoeren; B L Emmink; M J G Koerkamp; S R van Hooff; J A C M Goos; W J van Houdt; M de Wit; A M Prins; S R Piersma; T V Pham; E J Belt; H Bril; H B Stockmann; G A Meijer; R van Hillegersberg; F C Holstege; C R Jimenez; R J A Fijneman; O W Kranenburg; I H M Borel Rinkes Journal: Br J Cancer Date: 2013-09-03 Impact factor: 7.640